A 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patients

Gianluca Manni, Marco Centofanti, Mariacristina Parravano, Francesco Oddone, Massimo G. Bucci

Research output: Contribution to journalArticlepeer-review

Abstract

Background: New effective hypotensive agents have been recently introduced into clinical practice, but often more than one drug has to be used to prevent further visual field loss. The aim of this study was to evaluate the intraocular pressure (IOP)-lowering efficacy and safety of bimatoprost 0.03% compared with the association of timolol 0.5% and latanoprost 0.005% in open-angle glaucoma patients. Methods: In this 6-month, prospective, parallel, randomised, investigator-masked clinical trial, 61 glaucomatous patients treated with timolol 0.5% twice in both eyes were enrolled. The timolol 0.5% was replaced by bimatoprost 0.03% once daily (group I) or by latanoprost 0.005% plus timolol 0.5% (group II). IOP measurements were performed at the baseline visit and at days 15, 30, 60, 90, 120 and 180. Digital colour photography was used to evaluate topical side effects. Results: Fifty-six of the 61 patients were included for the intent-to-treat analysis (28 in group I and 28 in group II). Baseline mean IOP was similar in the two groups (p=0.5). Both treatments lowered the mean IOP at every visit significantly compared with the baseline (p

Original languageEnglish
Pages (from-to)767-770
Number of pages4
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Volume242
Issue number9
DOIs
Publication statusPublished - Sep 2004

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'A 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patients'. Together they form a unique fingerprint.

Cite this